Summary – A new market study, titled "Global Heart Failure Drugs Market Insights, Forecast to 2025" has been featured on WiseGuyReports.
The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.
The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China, and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.
One of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.
The global Heart Failure Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Heart Failure Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Heart Failure Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Heart Failure Drugs in these regions.
This research report categorizes the global Heart Failure Drugs market by top players/brands, region, type and end user. This report also studies the global Heart Failure Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
AstraZeneca
Bayer
Novartis
Gilead
GlaxoSmithKline
Pfizer
Teva Pharmaceutical industries
Market size by Product
Beta Blockers
ARBs
ACE Inhibitors
Market size by End User
Hospital
Pharmacy
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Heart Failure Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Heart Failure Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Heart Failure Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Heart Failure Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Heart Failure Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Heart Failure Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
For more details - https://www.wiseguyreports.com/reports/4119974-global-heart-failure-drugs-market-insights-forecast-to-2025
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +162-825-80070 (US)
Ph: +44 2035002763 (UK)
Additionally, this report provides insights on the factors that are driving and restraining the demand of Heart Failure Drugs market.
Furthermore, the study highlights and predicts the current market trends.
Furthermore, competitive analysis of Heart Failure Drugs market brings insights about the product profiles of the leading players.
Additionally, the analysis highlights the features and prices, informative reviews of the key products in the market.Get a Sample Copy of the Report at -https://www.industryresearch.co/enquiry/request-sample/13476167About Heart Failure Drugs Market Report: The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease.
However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics.
Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors.
Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug.
Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases.
They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors marketRheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues.
It causes joints to swell and can result in pain, stiffness, and progressive loss of function.
According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.What Drives the Market?1.
Growing prevalence of targeted therapies2.
According MarketsandMarkets Research – The Global Superdisintegrants Market is projected to reach USD 536.5 million by 2023 from USD 366.4 million in 2018, at a CAGR of 7.9% during the forecast period.Growth Opportunity: Pharmaceutical market expansion in emerging countries;The traditionally lucrative pharmaceuticals market is becoming challenging from a growth perspective due to the diminishing drug pipeline, government pressures to curtail healthcare costs, and the increasing regulations on innovative products.
This is encouraging pharmaceutical manufacturers to move their manufacturing bases closer to high-growth emerging markets.
Through this, manufacturers can take advantage of the low-cost manufacturing along with several financial benefits in terms of attractive tax rates and lenient regulatory guidelines for manufacturing in these countries.
A number of major excipient manufacturers are either planning capacity expansions of their existing plants in emerging countries or setting up new manufacturing plants in emerging markets such as China and India.Market Growth Drivers;# Growing Adoption of Orally Disintegrating Tablets# Growing Generics Market# Emergence of New Superdisintegrants for the Pharmaceutical IndustryRequest Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198068672Leading Key Players in the Worldwide Industry:The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US).Geographical Regions Mapped in Report:Europe is expected to account for the largest share of the superdisintegrants market in 2018, followed by North America and Asia Pacific.
The large share of this region can be attributed to the presence of a number of pharmaceutical giants with large production capacities leading to high consumption of excipients.
Moreover, a number of major global players are based in Germany.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198068672Market Segmentation in Detailed:Based on formulation, the superdisintegrants market is segmented into tablets and capsules.
[206 Pages Report] MarketsandMarkets forecasts the Empty Capsules market to grow from USD 1.95 billion in 2018 to USD 2.79 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period.
A softgel consists of a gelatin-based shell surrounding a liquid or semi-solid (inner fill) drug or extract in the center.
Softgel capsules offer several benefits to consumers such as convenience, enhanced efficacy, and bioavailability.
Enteric softgel capsules are expected to exhibit significant market growth during the forecast period, owing to rise in adoption of enteric softgel, surge in demand for omega-3 supplements, growth in promotional activities by manufacturers, and rise in consumer awareness for preventative healthcare.
The global softgel capsules market is estimated to grow at a CAGR of approximately 5% during the forecast period to reach approximately USD 2.5 billion by 2025.Market Dynamics1.
Over the years, capsule delivery has witnessed a number of technological advancements in terms of product enhancements for better quality outcomes and patient comfort.
